COEP

Coeptis Therapeutics, Inc. (COEP) | Rumor.io

Coeptis Therapeutics

COEP

Attention (50-day avg)0%

Attention rank (50-day avg)#4,479

Bullish sentiment (50-day avg)99%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about COEP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Mar 24

Coeptis Therapeutics, Inc. (COEP) filed its 10-K on the 19th, with a closing expected in Q2, but a supplemental filing was released yesterday, revealing an error in the original prospectus that may be the cause of the delay.
The company's merger plans have been cited as a reason for the stock's volatility, with some investors questioning the benefits for shareholders and the potential value of the shares.
The stock has broken support and is expected to drop further, with some analysts predicting a decline to the $9 area before a potential rebound to $11.

Generated by AI

Sentiment

Of the messages about COEP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% 0	84.84% -2.79
Bearish	0%	0%	0% 0	15.16% +2.79

Bullish· Jan 7

The low float of 1.5m shares makes the stock highly volatile and susceptible to wild price swings.
The company's news and announcements have been driving the stock's price up, with the author expecting more news to come, including potentially a major press release.
The stock's trend is supported by consistent higher highs and lows, with increasing buying interest and notable volume, indicating a strong upward momentum.

Bearish· Dec 27

$COEP is experiencing a significant sell-off, with some investors selling like "scared bitches" and others anticipating a price drop to as low as 13 cents.
The company's announcement of a reverse stock split has led to a decline in the stock's value, with some investors feeling that the move was already anticipated.
Short sellers are being pressured, with some investors anticipating a "massive loss" and others feeling that shorts are being "trapped" and will ultimately be "roasted".

Generated by AI

Topics

Of the messages about COEP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	75.82%
Analysts	—	—	—	0%
Controversies	—	—	—	0%
Earnings	—	—	—	1.96%
Macro	—	—	—	0%
Technical Analysis	—	—	—	22.22%

Nov 4

Coeptis Therapeutics has expanded its license agreement with Deverra Therapeutics to include pandemic preparedness and emergency use of its allogeneic natural killer cell technology.
The expanded license agreement broadens the potential applications of Coeptis' technology, including the use of unmodified NK cells in treating viral infections, pandemic-related illnesses, and emergency stockpiling for future health crises.
Coeptis' product portfolio includes a universal, multi-antigen CAR T technology and a cell therapy technology targeting CD38-related cancers, and the company is developing treatments for targeting cancer, autoimmune, and infectious diseases.

Generated by AI

Community

Of the messages about COEP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	73.1%
Newcomers	0%	0%	0%	26.9%

May 22

The company is focused on developing next-generation cell therapy technologies for cancer and infectious diseases, with a market-cap of $12.5 million and enough cash to fund operations for the foreseeable future.
Coeptis Therapeutics is working on a first-in-class universal SNAP-CAR NK cell therapy, which will be presented at a prestigious event, potentially sending the stock price up.
The company has made significant price movements, with a wild swing from a +50% upside to a -20% downside, and some traders are waiting for the right buy signals to jump back in, with a potential dip opportunity soon.

Generated by AI

News

Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating

Coeptis Therapeutics (NASDAQ: COEP) is pioneering a dual-track model designed to sustain innovation while reducing reliance on dilutive funding....

1mo agoBarchart.com

Also Discussed

Investors talking about COEP also mention

#	Name	Attention
1	NeuroOne Medical Technologies CorporationNMTC	0%0
2	P3 Health Partners Inc. Class A Common StockPIII	0%new
3	JFBR - Jeffs' Brands Ltd	——
4	Cardio Diagnostics Holdings, Inc.CDIO	0%0
5	SMFL - Smart for Life, Inc.	——
6	Silynxcom Ltd.SYNX	0%0
7	EBAC - European Biotech Acquisition Corp.	——
8	Foremost Clean Energy Ltd.FMST	0%0
9	MCTR - CTRL Group Limited Ordinary Shares	——
10	DIST - Distoken Acquisition Corporation	——